CC122 is a novel agent for DLBCL. It is an orally available pleiotropic pathway modulator. It has antitumor and immunomodulatory activity. It is used for the treatment of chronic lymphocytic leukemia. It binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL. It inhibits proliferation and induces apoptosis in ABC and GCB DLBCL in vitro. It was developed by Celgene Corporation(CELG) and was in clinic phase 2 trial.